[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354389-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354389-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immunetumor-cell-ligand-receptor-axes-driving-metabolic-reprogramming-and-therapeutic-resistance-in-cancer","Immune–tumor cell ligand– receptor axes driving metabolic reprogramming and therapeutic resistance in cancer","","Therapeutic resistance limits durable cancer control and cannot be fully explained by tumor-intrinsic genetic or epigenetic changes. Evidence shows that resistance arises in a dynamic tumor microenvironment where immune cells instruct tumor behavior via ligand–receptor (LR) signaling. Immune–tumor communication integrates inflammatory cues, checkpoint signals, chemokine networks, and metabolite-derived messages, driving metabolic reprogramming across glucose, lipid, amino acid, and redox pathways to support proliferation, stress tolerance, and immune evasion, while reducing therapy responsiveness.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immunetumor-cell-ligand-receptor-axes-driving-metabolic-reprogramming-and-therapeutic-resistance-in-cancer/354389/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immunetumor-cell-ligand-receptor-axes-driving-metabolic-reprogramming-and-therapeutic-resistance-in-cancer/354389.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do immune–tumor ligand–receptor axes contribute to therapeutic resistance?","Question",{"text":63,"@type":64},"They actively drive tumor metabolic reprogramming and help integrate immune suppression with metabolic adaptation, leading to reduced responsiveness to treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which signaling processes are highlighted as key regulators?",{"text":68,"@type":64},"Lactate-centered signaling, macrophage-derived cytokine/chemokine axes, and checkpoint-associated pathways such as PD-L1-related signaling are presented as major regulators.",{"name":70,"@type":61,"acceptedAnswer":71},"What technologies are used to map immune–tumor communication networks in situ?",{"text":72,"@type":64},"Single-cell transcriptomics, spatial omics, multiplex imaging, metabolomics, and computational modeling are described as accelerating mapping and identifying clinically relevant resistance niches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354389,1790872483,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 16 June 2026  \nDOI 10.3389/fimmu.2026.1864068  \nOPEN ACCESS  \nEDITED BY  \nSantosh Chokkakula,  \nChungbuk National University, Republic of Korea  \nREVIEWED BY  \nHongfei Jiang,  \nQingdao University, China Xudong Zhu,  \nUniversity of Kentucky, United States  \n*CORRESPONDENCE  \nBoxuan Zhou  \n[zhoubx@ncu.edu.cn](zhoubx@ncu.edu.cn)[ ](zhoubx@ncu.edu.cn)Rong Li  \n [lirong911@126.com](lirong911@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 24 April 2026  \nREVISED 29 May 2026  \nACCEPTED 01 June 2026  \nPUBLISHED 16 June 2026  \nCITATION  \nZhu H, Yi W, Wu Y, Li R and Zhou B (2026) Immune–tumor cell ligand– receptor axes driving metabolic reprogramming and therapeutic resistance in cancer.  \nFront. Immunol. 17:1864068 .  \ndoi: 10.3389/fimmu.2026.1864068  \nCOPYRIGHT  \n© 2026 Zhu, Yi, Wu, Li and Zhou. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImmune–tumor cell ligand– receptor axes driving metabolic reprogramming and therapeutic resistance in cancer  \nHailin Zhu 1†, Wang Yi 2†, Yujie Wu 3†, Rong Li 1* and Boxuan Zhou 2*  \n1 Department of Pathology, The Afﬁliated Cancer Hospital Of Gannan Medical University, Ganzhou, China, 2 Department of Breast Disease Center, The First Afﬁliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, China,  \n3 Hepatobiliary and Pancreatic Surgery, The Second Afﬁliated Hospital of Nanchang University, Second Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, China  \nTherapeutic resistance remains a major barrier to durable cancer control and cannot be fully explained by tumor-intrinsic genetic and epigenetic alterations alone. Increasing evidence indicates that resistance emerges within a dynamic tumor microenvironment in which immune cells actively instruct tumor cell behavior through ligand–receptor (LR) signaling. These immune–tumor communication axes link inﬂammatory cues, checkpoint-associated signals, chemokine networks, and metabolite-derived messages to adaptive tumor phenotypes. In particular, these axes may contribute to metabolic reprogramming across glucose, lipid, amino acid, and redox pathways, thereby supporting tumor-cell proliferation, therapeutic stress tolerance, and immune evasion. Lactate-centered signaling, macrophage-derived cytokine and chemokine axes, and checkpointassociated pathways such as PD-L1-related signaling have emerged as major regulators of this process. These LR-mediated circuits are increasingly associated with tumor metabolic remodeling, immune suppression, phenotypic plasticity, and reduced responsiveness to chemotherapy and immune checkpoint blockade. Recent advances in single-cell transcriptomics, spatial omics, multiplex imaging, metabolomics, and computational modeling are accelerating the mapping of these communication networks in situ and revealing clinically relevant resistance niches. In this review, we synthesize current evidence on how immune–tumor cell LR axes drive metabolic adaptation and therapeutic resistance across cancers, discuss the technologies enabling their dissection, and highlight their translational potential as biomarkers and therapeutic targets. Understanding these communication systems may provide new opportunities to disrupt resistant tumor ecosystems and improve the durability of cancer therapy.  \nKEYWORDS  \ndrug resistance, immune checkpoint, immune–tumor communication, lactate signaling, ligand–receptor axis, metabolic reprogramming, spatial omics, tumorassociated macrophages  \nFr","cbCais2ksKVHU896","https://ap.wps.com/l/cbCais2ksKVHU896","pdf",4109981,31,"English","# Highlights\n# Introduction","[{\"question\":\"How do immune–tumor ligand–receptor axes contribute to therapeutic resistance?\",\"answer\":\"They actively drive tumor metabolic reprogramming and help integrate immune suppression with metabolic adaptation, leading to reduced responsiveness to treatment.\"},{\"question\":\"Which signaling processes are highlighted as key regulators?\",\"answer\":\"Lactate-centered signaling, macrophage-derived cytokine/chemokine axes, and checkpoint-associated pathways such as PD-L1-related signaling are presented as major regulators.\"},{\"question\":\"What technologies are used to map immune–tumor communication networks in situ?\",\"answer\":\"Single-cell transcriptomics, spatial omics, multiplex imaging, metabolomics, and computational modeling are described as accelerating mapping and identifying clinically relevant resistance niches.\"}]","Immune–tumor cell ligand– receptor axes driving metabolic reprogramming and therapeutic resistance in cancer | PDF",1790110421,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83daad29f1888f2a866647a0951a9c2e.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fa5ada07cccd9f95afef073d32f431a.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a18faefd5d8848d877f175ef23bdd8cb.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf95312cb753033063725d78891ffe02.webp",980,1385]